CIDP Beacons 2026

Which statement best describes how CIDP affects you or your loved one’s abilities⁠?⁠*

I am a U.S. resident and I authorize argenx US Inc. (“argenx”), its affiliates, and companies working with argenx to use my contact information and health information (“Information”) to contact me by direct mail, email, telephone, and autodialed text message for marketing purposes, such as to provide me with information, offers, and promotions regarding chronic inflammatory demyelinating polyneuropathy, argenx products and programs, to conduct market research or surveys, and to use my Information to develop future products, services, and programs.

I understand that I may withdraw my authorization provided above by emailing privacy@argenx.com or following the unsubscribe instructions on the communication. Unless I withdraw this authorization, it will remain effective for 2 years. Copies of this authorization may be obtained by emailing privacy@argenx.com.